The immune landscape of human tumors: Implications for cancer immunotherapy

OncoImmunology

Volumn 3, Issue 1, 2014, Pages

  Bindea, Gabriela ^a,b,c   Mlecnik, Bernhard ^a,b,c   Angell, Helen K ^a,b,c,d   Galon, Jérôme ^a,b,c  

^a INSER M U872   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c CENTRE DE RECHERCHE DES CORDELIERS   (France)

^d ASTRAZENECA   (United Kingdom)

Author keywords

Bioinformatics; Cancer; Immune landscape; Immunoscore; Prognosis

Indexed keywords

CD3 ANTIGEN; CD45RO ANTIGEN; CD8 ANTIGEN; CXCL13 CHEMOKINE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; INTERLEUKIN 21; IPILIMUMAB; MESSENGER RNA; PROGRAMMED DEATH 1 RECEPTOR;

ADOPTIVE TRANSFER; ARTICLE; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CARCINOGENESIS; CELL INFILTRATION; CELLULAR IMMUNITY; COLORECTAL CARCINOMA; GENETIC VARIABILITY; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; LYMPHOCYTE SUBPOPULATION; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR RECURRENCE;

EID: 84899069873     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.27456     Document Type: Article

References (10)

1. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70; PMID:21436444; http://dx.doi. org/10.1126/science.1203486.
2. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pagès C, Tosolini M, Camus M, Berger A, Wind P, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 2006; 313:1960-4; PMID:17008531; http://dx.doi.org/10.1126/science.1129139.
3. Galon J, Fridman WH, Pagès F. The adaptive immunologic microenvironment in colorectal cancer: a novel perspective. Cancer Res 2007; 67:1883-6; PMID:17332313; http://dx.doi.org/10.1158/0008-5472.CAN-06-4806.
4. Galon J, Angell HK, Bedognetti D, Marincola FM. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013; 39:11-26; PMID:23890060; http://dx.doi.org/10.1016/j.immuni.2013.07.008.
5. Fridman WH, Pagès F, Sautès-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer 2012; 12:298-306; PMID:22419253; http://dx.doi.org/10.1038/nrc3245.
6. Galon J, Mlecnik B, Bindea G, Angell HK, Berger A, Lagorce C, Lugli A, Zlobec I, Hartmann A, Bifulco C, et al. Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. J Pathol 2014; 232:199-209; PMID:24122236; http://dx.doi. org/10.1002/path.4287.
7. Kalos M, June CH. Adoptive T cell transfer for cancer immunotherapy in the era of synthetic biology. Immunity 2013; 39:49-60; PMID:23890063; http://dx.doi.org/10.1016/j.immuni.2013.07.002.
8. Chen DS, Mellman I. Oncology meets immunology: the cancer-immunity cycle. Immunity 2013; 39:1-10; PMID:23890059; http://dx.doi.org/10.1016/j. immuni.2013.07.012.
9. Bindea G, Galon J, Mlecnik B. CluePedia Cytoscape plugin: pathway insights using integrated experimental and in silico data. Bioinformatics 2013; 29:661-3; PMID:23325622; http://dx.doi. org/10.1093/bioinformatics/btt019.
10. Bindea G, Mlecnik B, Tosolini M, Kirilovsky A, Waldner M, Obenauf AC, Angell H, Fredriksen T, Lafontaine L, Berger A, et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013; 39:782-95; PMID:24138885; http://dx.doi. org/10.1016/j.immuni.2013.10.003.